Naltrexone Depot: Phase III

In a 315-patient U.S. Phase III trial, patients receiving monthly injections of Naltrexone Depot plus psychotherapy met the primary endpoint of significantly more drink-free days after three months compared to patients given placebo plus psychotherapy on an intent-to-treat basis. The Naltrexone Depot patients had 10% more drink-free days than placebo (p=0.016). In addition, the company said that after 6 and 12 months, Naltrexone Depot patients had 20% and 73% more drink-free days than placebo (p=0.002 and p=0.0001, respectively). ...